#pTau_Assays

Alamar Biosciences Expands NULISAseq™ CNS Disease Panel with Innovative pTau Assays Alamar Biosciences announces the enhancement of its NULISAseq™ CNS Disease Panel 120 with groundbreaking pTau assays derived from brain samples. This advancement significantly improves the detection of neurodegenerative diseases.

Alamar Biosciences Expands NULISAseq™ CNS Disease Panel with Innovative pTau Assays #USA #Fremont #Alamar_Biosciences #NULISAseq #pTau_Assays

Alamar Biosciences Unveils New pTau Assays for Enhanced Neurodegenerative Disease Research Alamar Biosciences has expanded their groundbreaking NULISAseq™ CNS Disease Panel 120, adding innovative blood-based assays to detect brain-derived pTau proteins, enhancing neurodegenerative disease research.

Alamar Biosciences Unveils New pTau Assays for Enhanced Neurodegenerative Disease Research #United_States #Fremont #Alamar_Biosciences #NULISAseq #pTau_Assays

Alamar Biosciences Unveils Innovative pTau Assays for CNS Disease Detection Alamar Biosciences expands its innovative NULISAseq CNS Disease Panel 120 to include advanced blood-based pTau assays, enhancing neurodegenerative research.

Alamar Biosciences Unveils Innovative pTau Assays for CNS Disease Detection #USA #Fremont #Alamar_Biosciences #NULISAseq #pTau_Assays